News and Announcements
EDITORIAL
Cardiac regenerative therapy using induced pluripotent stem cells
Show Less
1
Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, New York,
United States of America
Submitted: 6 May 2024 | Accepted: 11 June 2024 |
(This article belongs to the Special Issue Exploring Cardiovascular Regenerative Therapy Using Induced Pluripotent Stem Cells)
© Invalid date by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Conflict of interest
The author declares no conflicts of interest.
References
- Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240-e327. doi: 10.1016/j.jacc.2013.05.019
- He L, Zhou B. Cardiomyocyte proliferation: Remove brakes and push accelerators. Cell Res. 2017;27:959-960. doi: 10.1038/cr.2017.91
- Yuasa S, Fukuda K. Cardiac regenerative medicine. Circ J. 2008;72(Suppl A):A49-A55. doi: 10.1253/circj.cj-08-0378.
- Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-676. doi: 10.1016/j.cell.2006.07.024
- Silver SE, Barrs RW, Mei Y. Transplantation of human pluripotent stem cell-derived cardiomyocytes for cardiac regenerative therapy. Front Cardiovasc Med. 2021; 8:707890. doi: 10.3389/fcvm.2021.707890